AZ-11645373

{{Drugbox | Verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (2R)-2-[[4-(4-fluorophenyl)piperazin-1-yl]methyl]-1,2,3,4-tetrahydroisoquinoline | image = AZ-11645373_structure.png | width = 200 | CAS_number = 123456-78-9 | PubChem = 12345678 | ChemSpiderID = 123456 | UNII = 123456789A | KEGG = D12345 | ChEMBL = 1234567 | C=20 | H=25 | F=1 | N=3 | O=0 | molecular_weight = 325.43 g/mol }}

AZ-11645373 is an experimental pharmaceutical compound developed by AstraZeneca for potential use in the treatment of various neurological disorders. It is primarily known for its action as a selective antagonist of the 5-HT6 receptor, a subtype of the serotonin receptor found predominantly in the central nervous system.

Pharmacology

AZ-11645373 functions as a potent and selective antagonist of the 5-HT6 receptor. The 5-HT6 receptor is implicated in the modulation of neurotransmitter release, including acetylcholine, dopamine, and glutamate, which are critical in cognitive processes such as learning and memory. By blocking this receptor, AZ-11645373 may enhance cognitive function and has been investigated for its potential in treating Alzheimer's disease and other forms of dementia.

Mechanism of Action

The mechanism by which AZ-11645373 exerts its effects involves the inhibition of the 5-HT6 receptor, which leads to increased levels of neurotransmitters in the synaptic cleft. This action is thought to improve synaptic plasticity and cognitive function, making it a candidate for cognitive enhancement therapies.

Clinical Development

As of the latest updates, AZ-11645373 is in the early stages of clinical development. Preclinical studies have shown promising results in animal models, demonstrating improved cognitive performance and neuroprotective effects. However, further clinical trials are necessary to establish its efficacy and safety in humans.

Potential Applications

The primary focus of AZ-11645373's development is in the treatment of cognitive disorders such as Alzheimer's disease. Its ability to modulate neurotransmitter systems also suggests potential applications in other neurological conditions, including schizophrenia and attention deficit hyperactivity disorder (ADHD).

Safety and Side Effects

As an experimental drug, the safety profile of AZ-11645373 is not fully established. Preliminary studies indicate that it is generally well-tolerated, but comprehensive clinical trials are required to determine any potential side effects and long-term safety concerns.

Also see

• 5-HT6 receptor
• Serotonin receptor
• Cognitive enhancer
• Alzheimer's disease
• Neurotransmitter

External links

• AstraZeneca Official Website
• ClinicalTrials.gov